These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16548113)

  • 1. Dextropropoxyphene combinations: Swedish market withdrawal.
    Prescrire Int; 2006 Feb; 15(81):20. PubMed ID: 16548113
    [No Abstract]   [Full Text] [Related]  

  • 2. Dextropropoxyphene: withdrawal from the US market requested: harmful drug.
    Prescrire Int; 2009 Aug; 18(102):166-7. PubMed ID: 19746529
    [No Abstract]   [Full Text] [Related]  

  • 3. Paracetamol + dextropropoxyphene: planned withdrawal from the British market.
    Prescrire Int; 2005 Aug; 14(78):145. PubMed ID: 16108102
    [No Abstract]   [Full Text] [Related]  

  • 4. Dextropropoxyphene: withdrawn in the EU. Withdrawn from pharmacies in France.
    Prescrire Int; 2009 Aug; 18(102):166. PubMed ID: 19746528
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of dextropropoxyphene + acetaminophen fixed-dose combination in psychiatric hospital in Bahrain: is there a cause for concern?
    Al Khaja KA; Al-Haddad MK; Al-Offi AR; Abdulraheem MH; Sequeira RP
    Fundam Clin Pharmacol; 2009 Apr; 23(2):253-8. PubMed ID: 19645819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dextropropoxyphene: welcome withdrawal from a French hospital's formulary.
    Prescrire Int; 2008 Jun; 17(95):112. PubMed ID: 18629970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dextropropoxyphene withdrawal from a French university hospital: impact on analgesic drug consumption.
    Gaubert S; Vié M; Damase-Michel C; Pathak A; Montastruc JL
    Fundam Clin Pharmacol; 2009 Apr; 23(2):247-52. PubMed ID: 19298233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Which analgesic after dextropropoxyphene withdrawal? A survey in a sample of general practitioners in southwest of France].
    Bismuth S; Leng EL; Oustric S; Montastruc JL; Lapeyre-Mestre M
    Therapie; 2011; 66(1):25-8. PubMed ID: 21466774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In the days of patients' choice, why is the patient being ignored?
    Scott DG
    Lancet; 2005 Jul 23-29; 366(9482):287-8. PubMed ID: 16039322
    [No Abstract]   [Full Text] [Related]  

  • 10. Profound metoprolol-induced bradycardia precipitated by acetaminophen-propoxyphene.
    Marraffa JM; Lang L; Ong G; Lehmann DF
    Clin Pharmacol Ther; 2006 Mar; 79(3):282-6. PubMed ID: 16513452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dextropropoxyphene-paracetamol and general convulsive crisis: case report].
    Lagnaoui R; Barcat D; Fach J; Bégaud B; Longy-Boursier M
    Therapie; 1999; 54(2):262-3. PubMed ID: 10394266
    [No Abstract]   [Full Text] [Related]  

  • 12. Co-proxamol (distalgesic) procurement in Bahrain. Policy implications for Gulf Cooperation Council countries.
    Al Khaja KA; Sequeira RP; Damanhori AH
    Med Princ Pract; 2009; 18(3):253-4. PubMed ID: 19349733
    [No Abstract]   [Full Text] [Related]  

  • 13. Propoxyphene (dextropropoxyphene): a critical review of a weak opioid analgesic that should remain in antiquity.
    Barkin RL; Barkin SJ; Barkin DS
    Am J Ther; 2006; 13(6):534-42. PubMed ID: 17122535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proctitis following the prolonged use of dextropropoxyphene and paracetamol suppositories: the risk persists despite change of excipient].
    Marteau P; Flourié B; Froguel E; Contou JF; Galian A; Rambaud JC
    Gastroenterol Clin Biol; 1990; 14(1):102-3. PubMed ID: 2311842
    [No Abstract]   [Full Text] [Related]  

  • 15. [Esophageal ulceration associated with ingestion of Di-Antalvic (a combination of dextropropoxyphene and paracetamol)].
    Finet L; Saleme R; Delcenserie R; Dupas JL
    Gastroenterol Clin Biol; 1990; 14(12):1033-4. PubMed ID: 2289668
    [No Abstract]   [Full Text] [Related]  

  • 16. [Dextropropoxyphene hepatotoxicity: four cases and literature review].
    Bergeron L; Guy C; Ratrema M; Beyens MN; Mounier G; Ollagnier M
    Therapie; 2002; 57(5):464-72. PubMed ID: 12611201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predominant central vestibular symptomatology caused by carbamazepine and dextropropoxyphene interaction].
    Bertholon P; Convers P; Lachheb N; Guy C; Martin C; Ollagnier M; Michel D
    Presse Med; 1997 Nov; 26(35):1675. PubMed ID: 9452747
    [No Abstract]   [Full Text] [Related]  

  • 18. It is time to remove propoxyphene from clinical practice.
    Lipman AG
    J Pain Palliat Care Pharmacother; 2009; 23(2):104-5. PubMed ID: 19492210
    [No Abstract]   [Full Text] [Related]  

  • 19. The dextropropoxyphene controversy.
    Bannwarth B; Richez C
    Joint Bone Spine; 2009 Oct; 76(5):449-51. PubMed ID: 19604717
    [No Abstract]   [Full Text] [Related]  

  • 20. Food and Drug Administration recommends against the continued use of propoxyphene.
    Food And Drug Administration Public Health Service U S Department Of Health And Human Services
    J Pain Palliat Care Pharmacother; 2011; 25(1):80-2. PubMed ID: 21426228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.